NEWARK, Del., Oct. 2, 2024 /PRNewswire/ -- Ambetter Health of Delaware, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Delawareans a variety of affordable health insurance plans in plan year 2025. Open enrollment for the Health Insurance Marketplace for Delaware runs from Nov. 1, 2024, through Dec. 15, 2024, for coverage starting Jan. 1, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"We're excited to continue providing affordable and dependable healthcare coverage options that fit the needs and lifestyles of Delawareans," said Plan President and Chief Executive Officer of Delaware First Health, Bill Wilson. "Ambetter Health of Delaware is committed to ensuring that quality healthcare is accessible for those who need it most."
Ambetter Health of Delaware offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Ambetter Health of Delaware will be offered in New Castle, Kent and Sussex counties in 2025.
Delaware residents interested in learning more about Ambetter Health of Delaware or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/de.
About Ambetter Health of Delaware
Ambetter Health of Delaware serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter Health of Delaware is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Delaware. For more information, please visit ambetterhealth.com/en/de/. This is a solicitation for insurance. For information on your right to receive an Ambetter Health of Delaware plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$64.80 |
Daily Change: | 0.98 1.54 |
Daily Volume: | 4,953,508 |
Market Cap: | US$34.090B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB